English
Français
Deutsch
Italiano
Português
Русский
Español
简体中文
日本語
AbCellera Biologics Inc. (ABCL) Piper Sandler 37th Annual Healthcare Conference December 3, 2025 8:00 AM EST
Company Participants
Martin Hogan
Conference Call Participants
Ashleigh Acker – Piper Sandler & Co., Research Division
Allison Bratzel – Piper Sandler & Co., Research Division
Presentation
Ashleigh Acker
Piper Sandler & Co., Research Division
Let’s go ahead and get started. My name is Ashleigh Acker, a biotech analyst on Allison Brassel’s team here at Piper Sandler.. Thank you for joining us at the Piper Sandler Healthcare Conference. It’s my pleasure to introduce AbCellera Biologics. Joining us today for a fireside chat, we have Senior Director of Strategic Finance and IR, Martin Hogan. Thank you for joining us for this fireside chat. This is meant to be an informal format. So if anyone in the audience has any questions, just raise your hand.
Question-and-Answer Session
Ashleigh Acker
Piper Sandler & Co., Research Division
So just to level set for investors, Martin, could you give a quick overview of the company, the AbCellera platform, what you’ve built over the last decade and where you are with partnered and pre-partnered programs? And then we’ll jump more into a fireside chat program with Q&A.
Martin Hogan
Absolutely. Well, first of all, thank you for hosting us, Ashleigh. It’s a pleasure to be here again. I will be making some forward-looking statements today. Please take a look at our SEC filings for a full description of the risks involved. Yes, when we think about AbCellera, we’re at a super exciting time in the company’s history. We started out really with a strong technological advantage based on searching deeply in natural immune systems for antibodies that could make good therapeutics.
And that was really a technological platform advantage that we had built coming out of the University of British
Read the full article here
